The Gulf Familial Hypercholesterolemia Registry (Gulf FH): Design, Rationale and Preliminary Results

Current Vascular Pharmacology - Tập 18 Số 1 - Trang 57-64 - 2019
Khalid Al‐Rasadi1, Khalid F. AlHabib2, Faisal A. Al-Allaf3, Khalid Al-Waili1, Ibrahim Al‐Zakwani4, Ahmad Al‐Sarraf5, Wael Almahmeed6, Nasreen Al-Sayed7, Mohammad Alghamdi8, Mohammed A. Batais9, Turky H. Almigbal9, Fahad Alnouri10, Abdulhalim Jamal Kinsara11, Ashraf Hammouda12, Zuhier Awan13, Heba Kary14, Omer A. Elamin14, Fahad Zadjali15, Mohammed Al‐Jarallah16, Abdullah Shehab17,18, Hani Sabbour6, Haitham Amin19, Hani Altaradi2
1Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman
2Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
3Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makka, Saudi Arabia
4Department of Pharmacology & Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
5Department of Medical Biochemistry, Ministry of Health, Kuwait City, Safat, Kuwait
6Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
7Gulf Diabetes Specialist Center, Manama, Bahrain
8National Guard Hospital, Riyadh, Saudi Arabia
9Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
10Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia
11King Saud bin Abdulaziz University for Health Sciences, College of Medicine, King Abdul Aziz Medical City, Jeddah, Saudi Arabia
12Saud Al Babtain Cardiac Center, Dammam, Saudi Arabia
13King Abdulaziz University, Jeddah, Saudi Arabia
14King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia
15Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
16Department of Medicine, Sabah Al-Ahmed Cardiac Center, Kuwait
17Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates
18University, Al Ain,United Arab Emirates
19Bahrain Defense Force Hospital, Riffa, Bahrain

Tóm tắt

Aim: To determine the prevalence, genetic characteristics, current management and outcomes of familial hypercholesterolaemia (FH) in the Gulf region. Methods: Adult (18-70 years) FH patients were recruited from 9 hospitals and centres across 5 Arabian Gulf countries. The study was divided into 4 phases and included patients from 3 different categories. In phase 1, suspected FH patients (category 1) were collected according to the lipid profile and clinical data obtained through hospital record systems. In phase 2, patients from category 2 (patients with a previous clinical diagnosis of FH) and category 1 were stratified into definitive, probable and possible FH according to the Dutch Lipid Clinic Network criteria. In phase 3, 500 patients with definitive and probable FH from categories 1 and 2 will undergo genetic testing for 4 common FH genes. In phase 4, these 500 patients with another 100 patients from category 3 (patients with previous genetic diagnosis of FH) will be followed for 1 year to evaluate clinical management and cardiovascular outcomes. The Gulf FH cohort was screened from a total of 34,366 patients attending out-patient clinics. Results: The final Gulf FH cohort consisted of 3,317 patients (mean age: 47±12 years, 54% females). The number of patients with definitive FH is 203. In this initial phase of the study, the prevalence of (probable and definite) FH is 1/232. Conclusion: The prevalence of FH in the adult population of the Arabian Gulf region is high. The Gulf FH registry, a first-of-a-kind multi-national study in the Middle East region, will help in improving underdiagnosis and undertreatment of FH in the region.

Từ khóa


Tài liệu tham khảo

Goldstein J.K.; Hobbs H.H.; Brown M.S.; In: Scriver CR, Beaud, Sly WS, Valle D (Eds), The metabolic & molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001; pp. 2863-913.

Austin M.A.; Hutter C.M.; Zimmern R.L.; Humphries S.E.; Genetic causes of monogenic heterozygous familial hypercholesterolemia: A Huge prevalence review. Am J Epidemiol 2004,160,407-420

Civeira F.; Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004,173,55-68

Rader D.J.; Cohen J.; Hobbs H.H.; Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003,111,1795-1803

Børge G.; Nordestgaard M.; Chapman J.; Humphries S.E.; Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013,34,3478-3490

Huijgen R.; Vissers M.N.; Defesche J.C.; Lansberg P.J.; Kastelein J.J.; Hutten B.A.; Familial hypercholesterolemia: Current treatment and advances in management. Expert Rev Cardiovasc Ther 2008,6,567-581

Raal F.J.; Santos R.D.; Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012,223,262-268

Shawar S.M.; Al-Drees M.A.; Ramadan A.R.; Ali N.H.; Alfadhli S.M.; The Arabic allele: A single base pair substitution activates a 10-base downstream cryptic splice acceptor site in exon 12 of LDLR and severely decreases LDLR expression in two unrelated Arab families with familial hypercholesterolemia. Atherosclerosis 2012,220,429-436

Al-Hinai A.T.; Al-Abri A.; Al-Dhuhli H.; First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene. Angiology 2013,64,287-292

Al-Rasadi K.; Al-Waili K.; Al-Zidi W.A.; Low-density lipoprotein receptor gene mutation analysis and structure-function correlation in an Omani Arab family with familial hypercholesterolemia. Angiology 2014,65,911-918

Al-Allaf F.A.; Athar M.; Abduljaleel Z.; Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Gene 2015,565,76-84

Alallaf F.H.; Nazar F.A.; Alnefaie M.; The spectrum of familial hypercholesterolemia (FH) in Saudi Arabia: Prime time for patient FH registry. Open Cardiovasc Med J 2017,11,66-75

Al-Rasadi K.; Al-Zakwani I.; Alsheikh-Ali A.A.; Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol 2018,12,685-692

Bamimore M.A.; Zaid A.; Banerjee Y.; Familial hypercholesterolemia mutations in the Middle Eastern and North African region: A need for a national registry. J Clin Lipidol 2015,9,187-194

Ruel I; Aljenedil S; Sadri I1, de Varennes É, et al. Imputation of baseline LDL cholesterol concentration in patients with familial hypercholesterolemia on statins or ezetimibe. Clin Chem 2017,64,355-362

Haralambos K.; Whatley S.D.; Edwards R.; Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 2015,240,190-196

Robinson J.T.; Thorvaldsdóttir H.; Winckler W.; Integrative genomics viewer. Nat Biotechnol 2011,29,24-26

Wang K.; Li M.; Hakonarson H.; ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010,38

el-Hazmi M.A.; al-Swailem A.R.; Warsy A.S.; Consanguinity among the Saudi Arabian population. J Med Genet 1995,32,623-626

Heiberg A.; Berg K.; The inheritance of hyperlipoproteinaemia with xanthomatosis. A study of 132 kindreds. Clin Genet 1976,9,203-233

Benn M.; Watts G.F.; Tybjaerg-Hansen A.; Nordestgaard B.G.; Familial hypercholesterolemia in the Danish general population: Prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012,97,3956-3964

Bellgard M.I.; Walker C.E.; Napier K.R.; Design of the Familial hypercholesterolaemia australasia network registry: Creating opportunities for greater international collaboration. J Atheroscler Thromb 2017,24,1075-1084

Batais M.A.; Almigbal T.H.; Bin Abdulhak A.A.; Altaradi H.B.; AlHabib K.F.; Assessment of physicians’ awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: Is there a gap? PLoS One 2017,12

Zubaid M.; Rashed W.A.; Almahmeed W.; Management and outcomes of Middle East patients admitted with acute coronary syndromes in the Gulf registry of acute coronary events (Gulf RACE). Acta Cardiol 2009,64,439-446

Alhabib K.F.; Sulaiman K.; Al-Motarreb A.; Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the second gulf registry of acute coronary events (Gulf RACE-2). Ann Saudi Med 2012,32,9-18

Zubaid M.; Thani K.B.; Rashed W.; Design and rationale of Gulf locals with acute coronary syndrome events (Gulf coast) registry. Open Cardiovasc Med J 2014,8,88-93

Henneman L.; McBride C.M.; Cornel M.C.; Duquette D.; Qureshi N.; Screening for Familial hypercholesterolemia in children: What can we learn from adult screening programs? Health Care 2015,3,1018-1030

De Backer G.; Besseling J.; Chapman J.; Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European society of cardiology. Atherosclerosis 2015,241,169-175

Nanchen D.; Gencer B.; Auer R.; Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J 2015,36,2438-2445

Wonderling D.; Umans-Eckenhausen M.A.; Marks D.; Defesche J.C.; Kastelein J.J.; Thorogood M.; Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands. Semin Vasc Med 2004,4,97-104

Nherera L.; Marks D.; Minhas R.; Thorogood M.; Humphries S.E.; Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011,97,1175-1181

Lázaro P.; Pérez de Isla L.; Watts G.F.; Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol 2017,11,260-271

Sturm A.C.; Knowles J.W.; Gidding S.S.; Clinical genetic testing for familial hypercholesterolemia. J Am Coll Cardiol 2018,72,662-680

Al Sayed N.; Al Waili K.; Alawadi F.; Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. Int J Cardiol 2016,225,268-283

Al Rasadi K.; Almahmeed W.; AlHabib K.F.; Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis 2016,252,182-187

Al-Ashwal A.; Alnouri F.; Sabbour H.; Identification and treatment of patients with homozygous familial hypercholesterolaemia: Information and recommendations from a Middle East advisory panel. Curr Vasc Pharmacol 2015,13,759-770

Arafah M.; Al-Hinai A.T.; Al Mahmeed W.; Centralized Middle East survey on the undertreatment of hypercholesterolemia: Results from the CEPHEUS study in Arabian Gulf countries. Angiology 2014,65,919-926

Nordestgaard B.G.; Chapman M.J.; Humphries S.E.; European atherosclerosis society consensus panel familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013,34,3478-3490

Hamilton-Craig I.; Kostner K.; Colquhoun D.; Woodhouse S.; Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2010,6,1023-1037

Cuchel M.; Bruckert E.; Ginsberg H.N.; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society. Eur Heart J 2014,35,2146-2157

Kastelein J.J.; Ginsberg H.N.; Langslet G.; ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015,36,2996-3003

Raal F.J.; Stein E.A.; Dufour R.; RUTHERFORD-2 investigators PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet 2015,385,331-340

Thông tin
Thông tin xuất bản

Current Vascular Pharmacology

Tập 18 Số 1

57-64

Thông tin tác giả